Mark Chen is an innovative and dedicated scientific leader with 27 years of experience at GlaxoSmithKline (GSK). Currently, they manage the vector and cell line development team in cell and gene therapy chemistry, manufacturing, and control (CMC), focusing on developing advanced bacterial artificial chromosome (BAC) stable cell line technology. Prior experience includes roles as Investigator and Group Leader at GSK, where they led biological reagent generation and assay development, and as a Postdoctoral Fellow at the MRC Protein Phosphorylation and Ubiquitylation Unit. Mark earned a Bachelor of Science degree in Genetics from Nankai University and a Doctor of Philosophy in Molecular Genetics from the University of Leicester.
This person is not in the org chart
This person is not in any teams
This person is not in any offices